ID: ALA385643

Max Phase: Preclinical

Molecular Formula: C16H17NaO5

Molecular Weight: 290.31

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc(C(=O)[O-])c(C=O)c2c1CC1(CCCCC1)O2.[Na+]

Standard InChI:  InChI=1S/C16H18O5.Na/c1-20-13-7-10(15(18)19)12(9-17)14-11(13)8-16(21-14)5-3-2-4-6-16;/h7,9H,2-6,8H2,1H3,(H,18,19);/q;+1/p-1

Standard InChI Key:  DLSDICLCCKZJFP-UHFFFAOYSA-M

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 290.31Molecular Weight (Monoisotopic): 290.1154AlogP: 2.84#Rotatable Bonds: 3
Polar Surface Area: 72.83Molecular Species: ACIDHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 3.88CX Basic pKa: CX LogP: 2.79CX LogD: -0.43
Aromatic Rings: 1Heavy Atoms: 21QED Weighted: 0.87Np Likeness Score: 0.85

References

1. Useglio M, Castellano PM, Operto MA, Torres R, Kaufman TS..  (2006)  Synthesis of 3H-spiro[benzofuran-2,1'-cyclohexane] derivatives from naturally occurring filifolinol and their classical complement pathway inhibitory activity.,  16  (19): [PMID:16875818] [10.1016/j.bmcl.2006.07.029]

Source